



1644  
PATENT

Case Docket No. MANNK.001CP2  
(formerly CTLIMM.001CP2)  
Date: August 22, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Kundig et al.  
App. No. : 09/776,232  
Filed : February 2, 2001  
For : METHOD OF INDUCING A CTL  
RESPONSE  
Examiner : Phuong Huynh  
Group Art Unit : 1644

Examiner Phuong Huynh  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Examiner Huynh:

Further to the Response to the Office Action filed via facsimile in the above-referenced case on August 13, 2003, enclosed are forty-seven (47) references cited as foreign patent documents and other documents in the Information Disclosure Statement (IDS), Paper No. 3, filed on May 3, 2001. In addition, for the convenience of the Examiner, a copy of the IDS is also enclosed.

As noted in the Office Action mailed April 14, 2003, these references were not submitted with the IDS filed on May 3, 2001 because they were previously submitted in the parent application (Application Serial No.: 09/380,534). The Examiner, however, was not able to locate the previously submitted references, and therefore, has requested that Applicants resubmit the references cited in the PTO Form 1449 as foreign patent documents and other documents. Accordingly, Applicants resubmit these references herewith.

**PATENT**

Case Docket No. MANNK.001CP2  
(formerly CTLIMM.001CP2)  
Date: August 22, 2003

---

If you have any questions or comments, please do not hesitate to contact me.

Sincerely,



Sheila R. Gibson  
Reg. No. 54,120

Enclosures

cc: Dale C. Hunt (w/o enclosures)  
Marc T. Morley (w/o enclosures)

S:\DOCS\SRG\SRG-1870.DOC\082003\lvo




PATENT

Case Docket No. CTLIMM.001CP2  
Date: May 3, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kündig, et al.  
Appl. No. : 09/776,232  
Filed : February 2, 2001  
For : A METHOD OF INDUCING  
A CTL RESPONSE  
Examiner : Unknown  
Group Art Unit : Unknown

I hereby certify that this correspondence and all  
marked attachments are being deposited with the  
United States Postal Service as first class mail in  
an envelope addressed to: Assistant Commissioner  
for Patents, Washington, D.C. 20231, on

May 3, 2001  
(Dale C. Hunt)  


Dale C. Hunt, Reg. No. 41,857

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231  
ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 listing one hundred and twenty-two (122) references; nine (9) references are enclosed herewith.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.



Dale C. Hunt  
Registration No. 41,857  
Attorney of Record



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COPY

Applicant	:	Kündig, et al.	)	Group Art Unit Unknown
App. No.	:	09/776,232	)	
Filed	:	February 2, 2001	)	
For	:	A METHOD OF INDUCING A CTL RESPONSE	)	
Examiner	:	Unknown	)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing one hundred and twenty-two (122) references. Enclosed herewith are references 26, 66, 90-91, and 112-116. The references 1-25, 27-65, 67-89, 92-111, and 117-122 were of record in U.S. Patent Application Serial No. 09/380,534, filed September 1, 1999, from which the above-identified application claims priority under 35 U.S.C §120. Accordingly, pursuant to 37 C.F.R. § 1.98(d), these references are not enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 3 May 2001

By:

Dale C. Hunt  
Registration No. 41,857  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
CTLIMM.001CP2APPLICATION NO.  
09/776,232

O I P E  
SEP 02 2003  
INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Kündig, et al.FILING DATE  
February 2, 2001GROUP  
Unknown

COPY

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
1	3,604,417	9/14/71	Stolzenberg et al.			
2	3,732,865	5/15/73	Higuchi, et al.			
3	3,760,804	9/25/73	Higuchi, et al.			
4	3,760,805	9/25/73	Higuchi			
5	3,760,984	9/25/73	Theeuwes			
6	3,929,132	12/30/75	Higuchi			
7	3,987,790	10/26/76	Eckenhoff, et al.			
8	3,995,631	12/7/76	Higuchi, et al.			
9	3,995,632	12/7/76	Nakano, et al.			
10	4,034,756	7/12/77	Higuchi, et al.			
11	4,203,440	5/20/80	Theeuwes			
12	4,286,067	8/25/81	Theeuwes			
13	4,300,558	11/12/81	Eckenhoff et al.			
14	4,304,232	12/8/81	Michaels			
15	4,340,048	7/20/82	Eckenhoff			
16	4,340,054	7/20/82	Michaels			
17	4,350,271	9/21/82	Eckenhoff			
18	4,367,741	1/11/83	Michaels			
19	4,435,173	3/6/84	Siposs et al.			
20	4,439,199	3/27/84	Armkraut et al.			
21	4,450,198	5/22/84	Michaels			
22	4,455,145	6/19/84	Theeuwes			
23	4,474,575	10/2/84	Eckenhoff, et al.			
24	4,498,843	2/12/85	Schneider et al.			
25	4,526,569	7/2/85	Bernardi			
26	4,552,651	11/12/85	Sandbrook, et al.			

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 <i>OIPF</i> SEP 02 2003 U.S. PATENT & TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.001CP2	APPLICATION NO. 09/776,232
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Kündig, et al.	
		FILING DATE February 2, 2001	GROUP Unknown

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	27	4,561,856	12/31/85	Cochran			
	28	4,619,652	10/28/86	Eckenhoff, et al.			
	29	4,643,723	2/17/87	Smit			
	30	4,753,651	6/28/88	Eckenhoff			
	31	4,767,628	8/30/88	Hutchinson et al.			
	32	4,838,862	6/13/89	Baker et al.			
	33	4,855,141	8/8/89	Eckenhoff, et al.			
	34	4,865,598	9/12/89	Eckenhoff			
	35	4,865,845	9/12/89	Eckenhoff, et al.			
	36	4,872,873	10/10/89	Zingerman			
	37	4,898,582	2/6/90	Faste			
	38	4,908,433	3/13/90	Mertlesmann et al.			
	39	4,929,233	5/29/90	Roth et al.			
	40	4,963,141	10/16/90	Eckenhoff			
	41	4,976,966	12/11/90	Theeuwes, et al.			
	42	5,017,381	5/21/91	Maruyama, et al.			
	43	5,023,088	6/11/91	Wong et al.			
	44	5,030,216	7/9/91	Theeuwes et al.			
	45	5,034,229	7/23/91	Magruder, et al.			
	46	5,037,420	8/6/91	Magruder, et al.			
	47	5,057,318	10/15/91	Magruder, et al.			
	48	5,059,423	10/22/91	Magruder, et al.			
	49	5,110,596	5/5/92	Magruder, et al.			
	50	5,110,597	5/5/92	Wong, et al.			
	51	5,135,498	8/4/92	Kam, et al.			
	52	5,135,523	8/4/92	Magruder, et al.			

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.001CP2	APPLICATION NO. 09/776,232
		APPLICANT Kündig, et al.	
		FILING DATE February 2, 2001	GROUP Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
53	5,137,727	8/11/92	Eckenhoff			
54	5,169,390	12/8/92	Athayde, et al.			
55	5,174,999	12/29/92	Magruder, et al.			
56	5,209,746	5/11/93	Balaban, et al.			
57	5,221,278	6/22/93	Linkwitz, et al.			
58	5,223,265	6/29/93	Wong			
59	5,257,987	11/2/93	Athayde et al.			
60	5,286,254	2/15/94	Shapland et al.			
61	5,304,165	4/19/94	Haber et al.			
62	5,368,562	11/29/94	Blomquist et al.			
63	5,478,556	12/26/95	Elliott et al.			
64	5,496,360	3/5/96	Hoffmann et al.			
65	5,580,859	12/03/96	Felgner et al.			
66	5,589,466	12/31/96	Felgner et al.			
67	5,679,647	10/21/97	Carson et al.			
68	5,698,396	12/16/97	Pfreundschuh			
69	5,733,548	03/31/98	Restifo et al.			
70	5,744,316	4/28/98	Lethe et al.			
71	5,747,269	5/5/98	Rammensee et al.			
72	5,846,540	12/08/98	Restifo et al.			
73	5,856,187	01/05/99	Restifo et al.			
74	5,962,428	10/05/99	Carrano et al.			
75	6,037,135	03/14/00	Kubo et al.			

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 <i>OPIE</i> SEP 02 2003 PATENT & TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.001CP2	APPLICATION NO. 09/776,232
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Kündig, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE February 2, 2001	GROUP Unknown

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	76 2,147,863	05/26/94	Canada				
	77 74899	08/13/97	Ireland				
	78 EP 93/03175	04/06/95	PCT				
	79 WO 92/21033	11/26/92	PCT				
	80 WO 95/17167	06/25/95	PCT				
	81 WO 96/01429	01/18/96	PCT				
	82 WO 96/27008	09/06/96	PCT				
	83 WO 96/40209	12/19/96	PCT				
	84 WO 98/13489	04/02/98	PCT				
	85 WO 98/14464	04/09/98	PCT				
	86 WO 98/27963	07/02/98	PCT				
	87 WO 98/43611	10/08/98	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
✓ 88	Bachman, M.F., et al. (1994) In vitro vs. in vivo assays for the assessment of T-and B cell function. Curr. Opin. Immunol. 6:320-326.	
✓ 89	Cleland, J.L., et al. (1994) Formulation and delivery of proteins and peptides. American Chemical Society, Acs Symposium Series No. 567.	
✓ 90	Courvalin, P. et al. (1995) Life Sci. 318:1207-1212.	
✓ 91	Dietrich, G. et al. (1998) Biotechnology 16:181-185.	
✓ 92	Durrant LG (1997) Cancer vaccines. Anti-cancer drugs. 8:727-733.	
✓ 93	Grohmann, U. et al. (1991) Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. Journal of Immunological Methods. 137:9-15.	
✓ 94	Haynes, B. F. et al. (1996) Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:324-327.	
✓ 95	Inaba, K., et al. (1992) Identification of proliferating dendritic cell precursors in mouse blood. Journal of Experimental Medicine. 175:1157-1167.	
✓ 96	Jager, E., et al. (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer. 67:54-62.	
✓ 97	Jager E. et al. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding Peptide Epitopes. J.Exp.Med. 187:265-270.	
✓ 98	Kündig, T.M. et al. (1992) Skin test to assess virus-specific cytotoxic T-cell activity. Proc. Natl. Acad. Sci. 89:7757-7761.	
✓ 99	Kündig, T.M. et al. (1995) Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science. 268:1343-1347.	

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 <i>O I P E</i> SEP 02 2003 USPTO PATENT & TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. CTLIMM.001CP2	APPLICATION NO. 09/776,232
		APPLICANT Kündig, et al.	
		FILING DATE February 2, 2001	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
✓	100 Kundig, T.M. et al. (1996) On the role of antigen in maintaining cytotoxic T cell memory. Proc. Natl. Acad. Sci. 93:9716-9723.
✓	101 Moskophidis D. et al. (1995) Immunobiology of Cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. Journal of Virology. 69:4:2187-2193.
✓	102 Oehen S. et al. (1992) Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. J.Exp.Med. 176:1273-1281.
✓	103 Oldstone, M. et al. (1995) Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. Journal of Virology. 69:12:7423-7429.
✓	104 Pantaleo G. et al. (1997) Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc. Natl. Acad. Sci. 94:9848-9853.
✓	105 Peters, R.I. et al. (1984) Tryptophan and serotonin metabolism after sustained tryptophan infusion. Neurochem. Int. 6:5:685-691.
✓	106 Pfeiffer, et al. "Insulin Pump Therapy" 3.1 to 3.2.4 pg. 14-33
✓	107 Puccetti P. et al. (1994) Use of skin test assay to determine tumor-specific CD8+ T cell reactivity. Eur. J. Immunol. 24:1446-1452.
✓	108 Rammensee, H.G. et al. (1995) MHC ligands and peptide motifs: first listing. Immunogenetics.41:178-228.
✓	109 Rammensee, H.G. et al. (1997) MHC ligands and peptide motifs. Landes Bioscience Austin Texas. Chapter 4:217-369.
✓	110 Remington (1985) The science and practice of pharmacy, Nineteenth Edition: Chapters 86-88.
✓	111 Santus G. et al. (1995) Osmotic drug delivery: a review of patent literature. Journal of Controlled Release. 35:1-21.
✓	112 Simard, John J.L., et al.; 09/560,465; April 28, 2000; EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS.
	113 Simard, John J.L., et al.; 09/561,074; April 28, 2000; METHOD OF EPITOPE DISCOVERY.
	114 Simard, John J.L., et al.; 09/561,571; April 28, 2000; EPITOPE CLUSTERS.
	115 Simard, John J.L., et al.; 09/561,572; April 28, 2000; EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS.
✓	116 Sizemore, D.R. et al. (1995) Science 270:299-302.
✓	117 Speiser, D.E. et al. (1997) Self antigens expressed by solid tumors do not efficiently stimulate naïve or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645-653.
✓	118 Steinman R.M. (1991) The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-296.
✓	119 Wiseman C. et al. (1993) Clinical responses to intralymphatic whole-cell melanoma vaccine augmented by in vitro incubation with alpha-interferon. Annals of the New York Academy of Sciences. 690:388-391.
✓	120 Wiseman C.L. et al. (1989) Clinical responses with active specific intralymphatic immunotherapy for cancer - A phase I-II trial. The Western Journal of Medicine. 151:283-288.
✓	121 Young J. W. et al. (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J.Exp.Med. 183:7-11.
✓	122 Zipkin I. (1998) Cancer vaccines. BioCentury. 6:A1-A6.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	